Sentences with phrase «for advanced tumors»

Not exact matches

But a late - stage clinical trial called CheckMate - 026 for the drug failed to meet its primary goal of halting cancer progression in advanced, untreated patients whose tumors consisted of at least 5 % PD - L1.

Patients in the trial had advanced NSCLC, and their tumors tested positive for PD - L1 levels of 50 % or more.

The FDA approved a Lutetium - 177 based cancer therapy called Lutathera for the treatment of neuroendocrine tumors earlier this year, after Novartis snapped up the developer, Advanced Accelerator, at a premium.

According to ICES Director J. Tinsley Oden, mathematical models of the invasion and growth of tumors in living tissue have been «smoldering in the literature for a decade,» and in the last few years, significant advances have been made.

The Moores Cancer Center's Molecular Tumor Board brought together medical, surgical and radiation therapy oncologists, biostatisticians, radiologists, pathologists, clinical geneticists, basic and translational science researchers, and bioinformatics and pathway analysis specialists to discuss the intricacies of tumor genetics and tailor a personalized treatment plan for patients with advanced cancer or who have exhausted standard theraTumor Board brought together medical, surgical and radiation therapy oncologists, biostatisticians, radiologists, pathologists, clinical geneticists, basic and translational science researchers, and bioinformatics and pathway analysis specialists to discuss the intricacies of tumor genetics and tailor a personalized treatment plan for patients with advanced cancer or who have exhausted standard theratumor genetics and tailor a personalized treatment plan for patients with advanced cancer or who have exhausted standard therapies.

«Several major advances in recent years have been good news for multiple myeloma patients, but those new drugs only target terminally differentiated cancer cells and thus can only reduce the bulk of the tumor,» said Jamieson, who is also deputy director of the Sanford Stem Cell Clinical Center, director of the CIRM Alpha Stem Cell Clinic at UC San Diego and director of stem cell research at Moores Cancer Center at UC San Diego Health.

«We now hope to design larger clinical studies to treat patients» tumors harboring these novel genomic aberrations to further explore the precise extent of clinical benefit for patients with primary or advanced cholangiocarcinoma.»

If hypofractionated radiation with curative intent can reduce the treatment time for lung cancer patients by half with no greater toxicity, and with equivalent — if not better — tumor control and survival outcomes, this research could result in a change in the paradigm of how a large subset of locally advanced NSCLC patients are treated.»

«As well as finding more effective treatments for advanced melanoma, we also need to stress the importance of early diagnosis, detecting tumors before they have a chance to spread.»

The Phase I clinical trial of OMP - 54F28 (FZD8 - Fc) is an open - label dose escalation study in patients with advanced solid tumors for which there was no remaining standard curative therapy.

«FDG PET shows tumor DNA levels in blood are linked to NSCLC aggressiveness: Insights derived from FDG PET could improve treatment selection for patients with advanced non-small cell lung cancer.»

For each of these cancer sites, the researchers calculated important regional and county differences in advanced stage of diagnosis, which takes into account the growth and size of the tumor and whether it has spread to the lymph nodes or other organs.

On its own, DON has shrunk tumors in clinical trials of people with a variety of advanced cancers, but its damage to the gastrointestinal system, a glutton for glutamine, ultimately proved too toxic for humans, say the scientists.

Advances such as a new understanding of cancer as a genomic disease and successes with immunotherapy — harnessing the immune system to thwart tumors — mean that «the time is right for a renewed surge against cancer,» they write.

EGFR tyrosine kinase inhibitor (TKI) therapy is approved for EGFR activating mutation positive patients with advanced NSCLC, but the standard for determining mutation status is with DNA derived directly from tumor tissue, which can be limited or not available.

Because bazedoxifene has already undergone safety and efficacy studies as a treatment for osteoporosis, it may be a viable near - term option for patients with advanced breast cancer whose tumors have become resistant to other treatment options, Wardell reported.

Loeb points out that much of the concern over cancer risk is that, as part of standard therapy for advanced prostate cancer, tumor growth is decreased by drugs that drastically reduce rather than increase male hormones.

In their report that has received advance online publication in Nature Nanotechnology, a research team based at the Wellman Center for Photomedicine at Massachusetts General Hospital (MGH) describes how a nanomedicine that combines photodynamic therapy — the use of light to trigger a chemical reaction — with a molecular therapy drug targeted against common treatment resistance pathways reduced a thousand-fold the dosage of the molecular therapy drug required to suppress tumor progression and metastatic outgrowth in an animal model.

«We have found that the individual cells within melanoma tumors are not all identical, and tumors contain a sub-population of cells that are inherently drug resistant, which accounts for the fact that advanced melanoma tumors return no matter how much the tumor is depleted,» said Meenhard Herlyn, D.V.M., D.Sc., professor and director of Wistar's Melanoma Research Center.

The main reason for advanced - stage ovarian cancer, they say, is an out of control protein CD44, which enables cancerous tumors to proliferate and become resistant to conventional drug treatments.

To explore this idea, Hopkins oncologists Dung Le, Luis Diaz, and others looked for mismatch repair mutations in tumor samples from patients with advanced colon cancer and other cancer types whose tumors had stopped responding to other treatments.

So for 17 patients with advanced melanoma who didn't have tumor - fighting T cells and had failed existing treatments, Rosenberg's team tried gene therapy.

Locally advanced pancreatic cancer has the lowest survival rate of any solid tumor, with a cumulative five - year survival rate of only 4 percent for all stages of disease.

«Metastatic brain tumors — often from lung, breast or skin cancers — are the most commonly observed tumors within the brain and account for about 40 percent of advanced melanoma metastases.

For tumor cells, the lymph nodes are a staging area and play a key role in advancing metastasis throughout the body.

«Metastatic brain tumors — often from lung, breast or skin cancers — are the most commonly observed tumors within the brain and account for about 30 percent of advanced breast cancer metastases,» says Khalid Shah, MS, PhD, director of the Molecular Neurotherapy and Imaging Laboratory in the MGH Departments of Radiology and Neurology, who led the study.

SNMMI NET Roadshow Advances in Nuclear Imaging and Therapy for Neuroendocrine Tumors August 24, 2017 Grand America Hotel Seattle, WA

LA JOLLA, CA — A close collaboration between researchers at the Salk Institute for Biological Studies and the Institute for Advanced Study found that the tumor suppressor p53, long thought of as...

For more information regarding Bristol - Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: • Early stage IB - IIIA, operable non-small cell lung cancer, confirmed in tissue • Lung function capacity capable of tolerating the proposed lung surgery • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 - 1 • Available tissue of primary lung tumor Exclusion Criteria: • Presence of locally advanced, inoperable or metastatic disease • Participants with active, known or suspected autoimmune disease • Prior treatment with any drug that targets T cell co-stimulations pathways (such as checkpoint inhibitors) Other protocol defined inclusion / exclusion criteria could apply

Inclusion Criteria: • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 • Have histologically or cytologically confirmed advanced or metastatic non-small cell lung cancer (NSCLC)(Stage IIIb or greater) • Measurable disease, as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 • Known PD - L1 tumor status as determined by an immunohistochemistry (IHC) assay performed by the central laboratory on tissue obtained at Screening • A woman of childbearing potential must have a negative highly sensitive serum (beta - human chorionic gonadotropin [beta - hCG]-RRB- at Screening within 14 days prior to study drug administration Inclusion Criteria for Crossover: • Participants must have been randomized to Arm A of the study and had radiographic disease progression according to RECIST 1.1 • Participants must have a mandatory biopsy at the time of disease progression according to RECIST 1.1 prior to crossing over.

Proton therapy is an advanced form of radiation treatment that is especially effective for reaching tumors or remaining cancer cells close to key organs such as the brain stem or spinal cord.

By characterizing mutations from secondary AML tumors in the MDS precursors for the same patient, the authors reconstructed the clonal architecture of the disease from early to advanced stages.

«Our results suggest that napabucasin might be an effective STAT3 inhibitor in patients with tumors positive for pSTAT3, and further investigation of napabucasin as monotherapy in advanced colorectal cancer is warranted in these patients,» wrote Derek J. Jonker, MD, of Ottawa Hospital Research Institute at the University of Ottawa, Canada, and colleagues.

The Maharaj Institute has an FDA IND clinical trial protocol (08001 - BMSCTI) for investigating a novel cancer therapy using transfusions of white blood cells from healthy donors to patient with advanced solid tumors.

Inclusion Criteria: • Availability of tumor tissue for mesothelin expression testing • Histologically - confirmed, mesothelin - expressing metastatic or advanced non-metastatic disease (tumour type specific inclusion criteria) • At least one measurable lesion according to either Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 or International Thymic Malignancy Interest Group (ITMIG) modified RECIST 1.1 as applicable • Adequate bone marrow, liver, renal and coagulation function • Left ventricular ejection fraction (LVEF) ≥ 50 % of the lower limit of normal (LLN) according to local institutional ranges • Eastern Cooperative Oncology Group (ECOG) 0 or 1 Exclusion Criteria: • More than one prior anti - tubulin / microtubule agent • Corneal epitheliopathy or any eye disorder that may predispose the patients to this condition • Symptomatic Central nervous system (CNS) metastases and / or carcinomatous meningitis • Contraindication to both CT and MRI contrast agents • Active hepatitis B or C infection • Pregnant or breast - feeding patients • Tumor type specific exclusion critumor tissue for mesothelin expression testing • Histologically - confirmed, mesothelin - expressing metastatic or advanced non-metastatic disease (tumour type specific inclusion criteria) • At least one measurable lesion according to either Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 or International Thymic Malignancy Interest Group (ITMIG) modified RECIST 1.1 as applicable • Adequate bone marrow, liver, renal and coagulation function • Left ventricular ejection fraction (LVEF) ≥ 50 % of the lower limit of normal (LLN) according to local institutional ranges • Eastern Cooperative Oncology Group (ECOG) 0 or 1 Exclusion Criteria: • More than one prior anti - tubulin / microtubule agent • Corneal epitheliopathy or any eye disorder that may predispose the patients to this condition • Symptomatic Central nervous system (CNS) metastases and / or carcinomatous meningitis • Contraindication to both CT and MRI contrast agents • Active hepatitis B or C infection • Pregnant or breast - feeding patients • Tumor type specific exclusion criTumor type specific exclusion criteria

One therapeutic tool they are advancing involves gathering pancreatic cancer cells from the bloodstream, assembling them into replicas of a patient's tumor and testing various drug combinations on the copies to develop personalized medicine for each patient.

Working together with a multidisciplinary team of cancer specialists, our department uses highly advanced cancer care techniques including multimodality imagaing for defining tumor volume, state - of - the - art intensity modulated radiation therapy (IMRT), MRI - based treatment planning, and interstitial brachytherapy using high dosage rate treatment.

The goal is to test if targeting the vitamin D receptor will unlock the potential of immunotherapies to kill pancreatic cancer tumor cells and potentially establish a therapeutic combination for controlling advanced pancreatic cancer, extending patient survival, and reducing patient side effects.

We identify and advance therapeutics into clinical trials for children with brain cancer, with increasing focus on types of brain tumors that are uncommon and have the greatest need for translational research.

This study design will establish whether (1) DAXX can serve as a marker for early tumor growth or later advanced / metastatic PCa, and (2) high DAXX expression associates with indolent versus lethal PCa.

Madsen's research focuses on the use of lasers in diagnostic and therapeutic medicine, the goal of which is to develop better treatments for patients with advanced brain tumors.

Guided by a world - renowned Scientific Advisory Council that includes three Nobel laureates and 26 members of the National Academy of Sciences, CRI has invested $ 336 million in support of research conducted by immunologists and tumor immunologists at the world's leading medical centers and universities, and has contributed to many of the key scientific advances that demonstrate the potential for immunotherapy to change the face of cancer treatment.

In our most advanced ZVex - based product candidate, CMB305, the vector carries the RNA for a tumor antigen called NY - ESO - 1 that is expressed in a wide range of tumors.

A study by Pauli and colleagues in this issue of Cancer Discovery describes the creation of a precision cancer platform for patients with advanced disease, integrating DNA sequencing of patient tumors with the generation of patient - derived organoids and xenografts.

Prof. Luis Liz - Marzan, EurASc Blaise Pascal Medalist in Materials Science in 2017, has received an ERC Advanced Grant for his project entitled «Four - Dimensional Monitoring of Tumour Growth by Surface Enhanced Raman Scattering» and this project will deal with the design of materials and methods that allow a study in real time of tumor growth under controlled environments, built from purposely designed scaffolds.

T - VEC, recently approved for the treatment of advanced melanoma, is an oncolytic herpes simplex virus type 1 engineered to replicate selectively in tumor cells and express human granulocyte - macrophage colony - stimulating factor.

«The approval of ipilimumab to treat advanced metastatic melanoma is a game changer not only for the thousands of people fighting this disease, but also for the entire field of oncology,» says Jill O'Donnell - Tormey, Ph.D., executive director of the Cancer Research Institute (CRI), a nonprofit organization that since 1953 has worked to advance the science of tumor immunology.

The cancer was advancing and when it became clear that chemotherapy would not halt the multiple tumor growth, IMC - C225 was tried for the first time, in a human.

Following graduation from OSU's veterinary college, she practiced for a year in Texas, then returned to OSU for advanced study of tumors.

Indications for radiation therapy (RT) include the primary treatment of specific tumor types, such as nasal tumors and brain tumors, adjuvant treatment of incompletely excised tumors, and palliation to improve quality of life for patients with non-resectable or advanced cancers.